Latest Hoffmann-La Roche Stories
WILTON, Conn., Feb. 28, 2012 /PRNewswire/ -- Private Client Resources, LLC (PCR), the premier provider of private wealth aggregation and data-driven solutions for wealth managers, advisory firms and family offices, has announced the continued adoption of its open architecture services have increased assets on their system by more than 220 percent in 2011. The growth in assets is the result of both new client acquisitions and the continued success of PCR's existing client...
ANN ARBOR, Mich. and AMSTERDAM, Feb. 23, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a company developing and commercializing sample-specific pre-analytical processes to improve the capabilities and performance of DNA and RNA analytical platforms, today announced a clinical supply agreement with molecular diagnostics firm Agendia for its TransPLEX® whole genome RNA amplification technology. Agendia will incorporate Rubicon's TransPLEX kits into the analysis of FFPE...
PLEASANTON, Calif., Feb. 22, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Life Technologies Corporation (LTC) announced today that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications. Under these two agreements, Roche has granted LTC an in vitro diagnostics product license to all of Roche's patents for real-time PCR (polymerase chain reaction) as well as other important PCR-related technology in the...
PENZBERG, Germany, February 22, 2012 /PRNewswire/ -- TATAA Biocenter [http://www.tataa.com ], Europe's leading provider of genomic services using quantitative real-time polymerase PCR (qPCR), is expanding its offerings to high-throughput gene expression profiling using Roche's RealTime ready Custom qPCR Assays and Panels. TATAA Biocenter's laboratories provide contract research for a full range of real-time qPCR services, including primer and probe design, validation, data...
On Jan. 18th 2012, the Honorable Judge Carol E. Higbee ordered an extended deadline for the sixth wave of core discovery for the Accutane lawsuit mass tort in New Jersey. Over 7,000 lawsuits have been filed in less than three years, since Accutane was pulled off the US market. Accutane is a popular acne medication specifically made to treat people who have extreme cases of acne. The lawsuits allege that Hoffman-LaRoche, the company manufacturing Accutane, failed to warn patients on the...
PENZBERG, Germany, February 15, 2012 /PRNewswire/ -- A research team led by Dr. Michel Bouvier at the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal in Quebec, used the Roche xCELLigence SP Instrument [https://www.roche-applied-science.com/sis/xcelligence/index.jsp?&id=xcect_030100 ] to measure changes in cell response following ligand stimulation (Stallaert et al., 2012, PloS ONE 7(1): e29420). According to their findings, selective...
PENZBERG, Germany, February 9, 2012 /PRNewswire/ -- In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University Medical Center Utrecht [http://www.umcutrecht.nl/zorg ] in the Netherlands, and Bioscience Department of AstraZeneca [http://www.astrazeneca.com/Home ] R&D, Molndal, Sweden, have tested Roche's xCELLigence Cardio Instrument. Their goal was to determine whether...
INDIANAPOLIS, Jan. 26, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria, to co-develop a complete range of coagulation assays. The alliance supports plans Roche announced in October 2011 to develop a new line of analyzers for the central coagulation lab, which will be marketed under Roche's...
A group of independent scientists has challenged the manufacturers of the anti-flu treatment Tamiflu to substantiate the treatment’s effectiveness by releasing previously withheld research data. In a recent report released by the non-profit Cochrane Collaboration, researchers stated that although Tamiflu does help relieve flu symptoms an average of 21 hours more quickly, it did not appear to reduce spread of the virus or the chances of being hospitalized for flu-related illnesses....
Healthhound.org appoints a researcher to buy alli weight loss pills. He will be reporting back on his findings on the site in 3 months time. Houston, TX. (PRWEB) December 17, 2011 Healthhound.org has just appointed a researcher to buy alli weight loss pills and see how much weight he can lose. He will then report back to the health hound readers in 3 months how the experiment went. Readers who are thinking of investing in the pills are welcome to check in with the site at that stage and...
